Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NeuroBo Pharmaceuticals (NRBO)
NASDAQ:NRBO
RESEARCH TOOLSreports
NeuroBo Pharmaceuticals (NRBO) Stock Price & Analysis
318 Followers
NRBO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.90 - $6.75
Previous Close$4.53
Volume27.41K
Average Volume (3M)59.08K
Market Cap
$25.68M
Enterprise Value-$52.80K
Total Cash (Recent Filing)$25.80M
Total Debt (Recent Filing)$65.00K
Price to Earnings (P/E)―
Beta-0.69
Next Earnings
Aug 13, 2024EPS Estimate
-$1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.26
Shares Outstanding4,906,002
10 Day Avg. Volume20,194
30 Day Avg. Volume59,084
Standard Deviation0.25
R-Squared0.00397
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.92
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.00Price Target Upside120.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
NeuroBo Pharmaceuticals News
PremiumCompany Announcements
NeuroBo Pharmaceuticals Enhances Equity Plan and Elects Directors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NRBO FAQ
What was NeuroBo Pharmaceuticals’s price range in the past 12 months?
NeuroBo Pharmaceuticals lowest stock price was $2.90 and its highest was $6.75 in the past 12 months.
What is NeuroBo Pharmaceuticals’s market cap?
Currently, no data Available
When is NeuroBo Pharmaceuticals’s upcoming earnings report date?
NeuroBo Pharmaceuticals’s upcoming earnings report date is Aug 13, 2024 which is in 37 days.
How were NeuroBo Pharmaceuticals’s earnings last quarter?
NeuroBo Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$1.32 earnings per share for the quarter, missing the consensus estimate of -$1.1 by -$0.22.
Is NeuroBo Pharmaceuticals overvalued?
According to Wall Street analysts NeuroBo Pharmaceuticals’s price is currently Undervalued.
Does NeuroBo Pharmaceuticals pay dividends?
NeuroBo Pharmaceuticals does not currently pay dividends.
What is NeuroBo Pharmaceuticals’s EPS estimate?
NeuroBo Pharmaceuticals’s EPS estimate is -$1.42.
How many shares outstanding does NeuroBo Pharmaceuticals have?
NeuroBo Pharmaceuticals has 5,669,361 shares outstanding.
What happened to NeuroBo Pharmaceuticals’s price movement after its last earnings report?
NeuroBo Pharmaceuticals reported an EPS of -$1.32 in its last earnings report, missing expectations of -$1.1. Following the earnings report the stock price went up 1.781%.
Which hedge fund is a major shareholder of NeuroBo Pharmaceuticals?
Currently, no hedge funds are holding shares in NRBO
---
NeuroBo Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (120.75% Upside)
$10.00 (120.75% Upside)
Blogger Sentiment
Bullish
NRBO Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $8.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.86%
12-Months-Change
Fundamentals
Return on Equity
-108.42%
Trailing 12-Months
Asset Growth
-45.95%
Trailing 12-Months
Company Description
NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders. The company was founded on October 30, 2014 and is headquartered in Boston, MA.
---
NRBO Stock 12 Month Forecast
Average Price Target
$10.00
▲(120.75% Upside)
Technical Analysis
Voyager Therapeutics
―
Assembly Biosciences
―
Axsome Therapeutics
―
Syndax Pharmaceuticals
―
Best Analysts Covering NRBO
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+15.20%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.20% per trade.
---